Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 323 of the 326 references it cites were found in a registry or an index.

The Lancet Global Health Commission on Global Eye Health: vision beyond 2020

Open access

Abstract

Eye health and vision have widespread and profound implications for many aspects of life, health, sustainable development, and the economy.Yet nowadays, many people, families, and populations continue to suffer the consequences of poor access to high-quality, affordable eye care, leading to vision impairment and blindness.In 2020, an estimated 596 million people had distance vision impairment worldwide, of whom 43 million were blind.Another 510 million people had uncorrected near vision impairment, simply because of not having reading spectacles.A large proportion of those affected (90%), live in low-income and middle-income countries (LMICs).However, encouragingly, more than 90% of people with vision impairment have a preventable or treatable cause with existing highly cost-effective interventions.Eye conditions affect all stages of life, with young children and older people being particularly affected.Crucially, women, rural populations, and ethnic minority groups are more likely to have vision impairment, and this pervasive inequality needs to be addressed.By 2050, population ageing, growth, and urbanisation might lead to an estimated 895 million people with distance vision impairment, of whom 61 million will be blind.Action to prioritise eye health is needed now.This Commission defines eye health as maximised vision, ocular health, and functional ability, thereby contributing to overall health and wellbeing, social inclusion, and quality of life.Eye health is essential to achieve many of the Sustainable Development Goals (SDGs).Poor eye health and impaired vision have a negative effect on quality of life and restrict equitable access to and achievement in education and the workplace.Vision loss has substantial financial implications for affected individuals, families, and communities.Although high-quality data for global economic estimates are scarce, particularly for LMICs, conservative assessments based on the latest prevalence figures for 2020 suggest that annual global productivity loss from vision impairment is approximately US$410•7 billion purchasing power parity.Vision impairment reduces mobility, affects mental wellbeing, exacerbates risk of dementia, increases likelihood of falls and road traffic crashes, increases the need for social care, and ultimately leads to higher mortality rates.By contrast, vision facilitates many daily life activities, enables better educational outcomes, and increases work productivity, reducing inequality.An increasing amount of evidence shows the potential for vision to advance the SDGs, by contributing towards poverty reduction, zero hunger, good health and wellbeing, quality education, gender equality, and decent work.Eye health is a global public priority, transforming lives in both poor and wealthy communities.Therefore, eye health needs to be reframed as a development as well as a health issue and given greater prominence within the global development and health agendas.Vision loss has many causes that require promotional, preventive, treatment, and rehabilitative interventions.Cataract, uncorrected refractive error, glaucoma, agerelated macular degeneration, and diabetic retinopathy www.thelancet.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2214-109x(20)30488-5

Cites

323 of 323 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The development of global eye health Blue circles indicate major global developments. Red circles indicate major treatments and programmatic developments. WHA=World Health Assembly. IAPB=International Agency for the Prevention of Blindness. RAAB=Rapid Assessment of Avoidable Blindness. RACSS=Rapid Assessment of Cataract Surgical Services.
Figure 1 The development of global eye health Blue circles indicate major global developments. Red circles indicate major treatments and programmatic developments. WHA=World Health Assembly. IAPB=International Agency for the Prevention of Blindness. RAAB=Rapid Assessment of Avoidable Blindness. RACSS=Rapid Assessment of Cataract Surgical Services.CC BY · PubMed Central
Figure 2 The human eye and common conditions The location and clinical appearance of common causes of vision impairment.
Figure 2 The human eye and common conditions The location and clinical appearance of common causes of vision impairment.CC BY · PubMed Central
Figure 3 Life course perspective on eye health Arrows indicate the period in the life course in which different conditions typically present. The yellow line indicates a hypothetical functional vision trajectory of someone with a condition leading to increased vision impairment. The black line represents the functional vision trajectory of someone who does not have a condition leading to vision impairment. This figure is partly based on the concept of functional trajectories illustrated in WHO, 2001.12 The disability threshold represents the level of functional vision below which there is functional vision impairment.
Figure 3 Life course perspective on eye health Arrows indicate the period in the life course in which different conditions typically present. The yellow line indicates a hypothetical functional vision trajectory of someone with a condition leading to increased vision impairment. The black line represents the functional vision trajectory of someone who does not have a condition leading to vision impairment. This figure is partly based on the concept of functional trajectories illustrated in WHO, 2001.12 The disability threshold represents the level of functional vision below which there is functional vision impairment.CC BY · PubMed Central
Figure 4 Improving eye health and Sustainable Development Goals Green arrows indicate relationships with direct evidence of a beneficial effect from improving eye health on Sustainable Development Goals. Dashed green arrows represent hypothesised direct beneficial effects. Black arrows represent possible indirect beneficial effects.
Figure 4 Improving eye health and Sustainable Development Goals Green arrows indicate relationships with direct evidence of a beneficial effect from improving eye health on Sustainable Development Goals. Dashed green arrows represent hypothesised direct beneficial effects. Black arrows represent possible indirect beneficial effects.CC BY · PubMed Central
Figure 5 Relationships between vision impairment and general health These associations are derived from multiple literature reviews done by this Commission. *Hypothetical common degenerative pathways.
Figure 5 Relationships between vision impairment and general health These associations are derived from multiple literature reviews done by this Commission. *Hypothetical common degenerative pathways.CC BY · PubMed Central
Figure 6 Vision impairment and mortality Random-effects meta-analysis results showing the maximally adjusted pooled hazard of mortality in adults with (A) mild vision impairment or worse (<6/12 compared with ≥6/12); (B) moderate vision impairment or worse (<6/18 compared with ≥6/18); (C) severe vision impairment or worse (<6/60 compared with ≥6/18); and (D) severe vision impairment or worse (<6/60 compared with ≥6/60). Events are defined as the number of participants in the study who died, and N is the total number of participants in the study. 12 cohorts that were included in the systematic review are not depicted in this figure for the following reasons: they used other vision impairment thresholds that could not be aggregated with these studies; they reported results per unit difference in visual acuity; they reported odds ratios or risk ratios that could not be pooled with HRs; or they compared a reference category of participants with good vision to participants with various vision impairment categories. References can be found in appendix 1 (p 100).
Figure 6 Vision impairment and mortality Random-effects meta-analysis results showing the maximally adjusted pooled hazard of mortality in adults with (A) mild vision impairment or worse (<6/12 compared with ≥6/12); (B) moderate vision impairment or worse (<6/18 compared with ≥6/18); (C) severe vision impairment or worse (<6/60 compared with ≥6/18); and (D) severe vision impairment or worse (<6/60 compared with ≥6/60). Events are defined as the number of participants in the study who died, and N is the total number of participants in the study. 12 cohorts that were included in the systematic review are not depicted in this figure for the following reasons: they used other vision impairment thresholds that could not be aggregated with these studies; they reported results per unit difference in visual acuity; they reported odds ratios or risk ratios that could not be pooled with HRs; or they compared a reference category of participants with good vision to participants with various vision impairment categories. References can be found in appendix 1 (p 100).CC BY · PubMed Central
Figure 7 Vision impairment by Global Burden of Disease region (A) Age-standardised prevalence of vision impairment and (B) number of people with vision impairment. Data from VLEG–GBD.1 MSVI=moderate and severe vision impairment.
Figure 7 Vision impairment by Global Burden of Disease region (A) Age-standardised prevalence of vision impairment and (B) number of people with vision impairment. Data from VLEG–GBD.1 MSVI=moderate and severe vision impairment.CC BY · PubMed Central
Figure 8 Causes of vision impairment by Global Burden of Disease region (A) Blindness and (B) moderate and severe vision impairment attributable to the five leading causes of vision impairment and other conditions (combined), all ages. Data are presented for the 21 Global Burden of Disease regions. Data from VLEG–GBD.131
Figure 8 Causes of vision impairment by Global Burden of Disease region (A) Blindness and (B) moderate and severe vision impairment attributable to the five leading causes of vision impairment and other conditions (combined), all ages. Data are presented for the 21 Global Burden of Disease regions. Data from VLEG–GBD.131CC BY · PubMed Central
Figure 9 Forecast to 2050 of global cases of blindness and vision impairment by sex Reproduced from VLEG–GBD, 2020.1
Figure 9 Forecast to 2050 of global cases of blindness and vision impairment by sex Reproduced from VLEG–GBD, 2020.1CC BY · PubMed Central
Figure 10 Women with blindness and MSVI Excess number of women over men, in adults (≥50 years). Data are plotted for the 21 Global Burden of Disease regions using a log scale. Size of the circle represents the total number of adults with blindness and MSVI in that region. Oceania has less than 1000 excess women with MSVI and was not plotted on this figure. Data available in appendix 1 (p 33), from VLEG–GBD.1 MSVI=moderate and severe vision impairment.
Figure 10 Women with blindness and MSVI Excess number of women over men, in adults (≥50 years). Data are plotted for the 21 Global Burden of Disease regions using a log scale. Size of the circle represents the total number of adults with blindness and MSVI in that region. Oceania has less than 1000 excess women with MSVI and was not plotted on this figure. Data available in appendix 1 (p 33), from VLEG–GBD.1 MSVI=moderate and severe vision impairment.CC BY · PubMed Central
Figure 11 Most recent population-based eye health surveys globally All surveys (rapid and comprehensive, national or subnational) done since 2000. Not applicable indicates that no surveys were done. Data from VLEG–GBD,1 and the Rapid Assessment of Avoidable Blindness Repository.
Figure 11 Most recent population-based eye health surveys globally All surveys (rapid and comprehensive, national or subnational) done since 2000. Not applicable indicates that no surveys were done. Data from VLEG–GBD,1 and the Rapid Assessment of Avoidable Blindness Repository.CC BY · PubMed Central
Figure 12 Productivity losses resulting from vision impairment Estimates made for 2020 using the number of people who were blind or had moderate and severe vision impairment, an employment gap of 30·2%, 2018 employment rates, and gross domestic product for (A) productivity loss, and (B) as a percentage of gross domestic product.
Figure 12 Productivity losses resulting from vision impairment Estimates made for 2020 using the number of people who were blind or had moderate and severe vision impairment, an employment gap of 30·2%, 2018 employment rates, and gross domestic product for (A) productivity loss, and (B) as a percentage of gross domestic product.CC BY · PubMed Central
Figure 13 Cost-effectiveness ratios for cataract surgery Studies reporting either DALYs averted or QALYs gained. Costs have been inflated to 2018 levels and converted to US$ purchasing power parity. Studies which provide only a single estimate are plotted as a diamond. For studies reporting more than one estimation the highest and lowest values are plotted as a range (appendix 1 pp 56–57). Letters shown next to some regions are related to the WHO regional coding labels. References for this figure can be found in appendix 1 (p 101). DALYs=disability-adjusted life-years. ECCE=extracapsular cataract surgery. QALYs=quality-adjusted life-years. SICS=small-incision cataract surgery.
Figure 13 Cost-effectiveness ratios for cataract surgery Studies reporting either DALYs averted or QALYs gained. Costs have been inflated to 2018 levels and converted to US$ purchasing power parity. Studies which provide only a single estimate are plotted as a diamond. For studies reporting more than one estimation the highest and lowest values are plotted as a range (appendix 1 pp 56–57). Letters shown next to some regions are related to the WHO regional coding labels. References for this figure can be found in appendix 1 (p 101). DALYs=disability-adjusted life-years. ECCE=extracapsular cataract surgery. QALYs=quality-adjusted life-years. SICS=small-incision cataract surgery.CC BY · PubMed Central
Figure 14 Cost-effectiveness ratios for refractive error services Cost-effectiveness of screening and treating refractive error in schoolchildren166, 167 and for facility-based refractive error services for all ages.165 Studies reported either DALYs averted or QALYs gained. Costs have been inflated to 2018 levels and converted to US$ purchasing power parity. For studies reporting more than one estimation, the highest and lowest values are plotted as a range (appendix 1 p 57). References for this figure can be found in appendix 1 (p 101).
Figure 14 Cost-effectiveness ratios for refractive error services Cost-effectiveness of screening and treating refractive error in schoolchildren166, 167 and for facility-based refractive error services for all ages.165 Studies reported either DALYs averted or QALYs gained. Costs have been inflated to 2018 levels and converted to US$ purchasing power parity. For studies reporting more than one estimation, the highest and lowest values are plotted as a range (appendix 1 p 57). References for this figure can be found in appendix 1 (p 101).CC BY · PubMed Central
Figure 15 Global distribution of research Number of primary research studies on vision and eye health, by country, done between 2000 and 2019 (studies identified by “explode eye disease” on MEDLINE, July 10, 2020; n=156 954; appendix 1 pp 58–59).
Figure 15 Global distribution of research Number of primary research studies on vision and eye health, by country, done between 2000 and 2019 (studies identified by “explode eye disease” on MEDLINE, July 10, 2020; n=156 954; appendix 1 pp 58–59).CC BY · PubMed Central
Figure 16 Considerations for universal eye health coverage Adapted from WHO 2015,185 to contextualise to eye health services and include the quality component. The inner cube has a colour gradation representing a range in the quality of delivered services; green represents effective quality services and blue represents ineffective services.
Figure 16 Considerations for universal eye health coverage Adapted from WHO 2015,185 to contextualise to eye health services and include the quality component. The inner cube has a colour gradation representing a range in the quality of delivered services; green represents effective quality services and blue represents ineffective services.CC BY · PubMed Central
Figure 17 Integration of eye health services within the health-care system
Figure 17 Integration of eye health services within the health-care systemCC BY · PubMed Central
Figure 18 Vision impairment and eye health workforce Shown for the Global Burden of Disease regions. (A) Age-standardised prevalence of blindness (all ages) by the number of ophthalmologists per million population. The circle area is proportional to the number of people who are blind. (B) Age-standardised prevalence of vision impairment (mild, moderate, severe, and blind; all ages) by the number of ophthalmologists and optometrists per million population. The circle area is proportional to the number of people who have vision impairment. Data from Resnikoff et al,266 VLEG–GBD,1 and World Council of Optometry.257
Figure 18 Vision impairment and eye health workforce Shown for the Global Burden of Disease regions. (A) Age-standardised prevalence of blindness (all ages) by the number of ophthalmologists per million population. The circle area is proportional to the number of people who are blind. (B) Age-standardised prevalence of vision impairment (mild, moderate, severe, and blind; all ages) by the number of ophthalmologists and optometrists per million population. The circle area is proportional to the number of people who have vision impairment. Data from Resnikoff et al,266 VLEG–GBD,1 and World Council of Optometry.257CC BY · PubMed Central
Figure 19 Effective coverage cascade for cataract surgical services CSC=cataract surgical coverage. eCSC=effective cataract surgical coverage.
Figure 19 Effective coverage cascade for cataract surgical services CSC=cataract surgical coverage. eCSC=effective cataract surgical coverage.CC BY · PubMed Central
Figure 20 Cataract surgical rate by Global Burden of Disease super region Box and whisker plots; midlines are the median, boxes represent IQR, whiskers are upper and lower adjacent values. Outliers are plotted as individual dots.
Figure 20 Cataract surgical rate by Global Burden of Disease super region Box and whisker plots; midlines are the median, boxes represent IQR, whiskers are upper and lower adjacent values. Outliers are plotted as individual dots.CC BY · PubMed Central
Figure 21 Effective cataract surgical coverage by Global Burden of Disease super region (A) Cluster-adjusted, age-adjusted, and sex-adjusted estimates. (B) Cluster-adjusted, age-adjusted, and sex-disaggregated estimates. Box and whisker plots; midlines are the median, boxes represent IQR, whiskers are upper and lower adjacent values. Outliers are plotted as individual dots. Countries within regions are represented by the most recent national or subnational Rapid Assessment of Avoidable Blindness survey and if two or more assessments occurred within 2 years, the median of estimates was used (appendix 1 pp 84–85).
Figure 21 Effective cataract surgical coverage by Global Burden of Disease super region (A) Cluster-adjusted, age-adjusted, and sex-adjusted estimates. (B) Cluster-adjusted, age-adjusted, and sex-disaggregated estimates. Box and whisker plots; midlines are the median, boxes represent IQR, whiskers are upper and lower adjacent values. Outliers are plotted as individual dots. Countries within regions are represented by the most recent national or subnational Rapid Assessment of Avoidable Blindness survey and if two or more assessments occurred within 2 years, the median of estimates was used (appendix 1 pp 84–85).CC BY · PubMed Central
Figure 22 Cataract surgical coverage in Vietnam (A) Cluster-adjusted, age-adjusted, and gender-adjusted data from subnational Rapid Assessment of Avoidable Blindness surveys done in Vietnam in 2000–02 (n=8), 2007 (n=16), and 2015 (n=14), estimated for an operable cataract threshold of worse than 6/60 and a good clinical outcome of 6/18 or greater. (B) Data from 14 subnational surveys done in Vietnam in 2015. Data are plotted for three thresholds of operable cataract and two different levels of vision outcome: 6/18 or better and 6/12 or better. Box and whisker plots; midlines are the median, boxes represent IQR, whiskers are upper and lower adjacent values. Outliers are plotted as individual dots. CSC=cataract surgical coverage. eCSC=effective cataract surgical coverage.
Figure 22 Cataract surgical coverage in Vietnam (A) Cluster-adjusted, age-adjusted, and gender-adjusted data from subnational Rapid Assessment of Avoidable Blindness surveys done in Vietnam in 2000–02 (n=8), 2007 (n=16), and 2015 (n=14), estimated for an operable cataract threshold of worse than 6/60 and a good clinical outcome of 6/18 or greater. (B) Data from 14 subnational surveys done in Vietnam in 2015. Data are plotted for three thresholds of operable cataract and two different levels of vision outcome: 6/18 or better and 6/12 or better. Box and whisker plots; midlines are the median, boxes represent IQR, whiskers are upper and lower adjacent values. Outliers are plotted as individual dots. CSC=cataract surgical coverage. eCSC=effective cataract surgical coverage.CC BY · PubMed Central
Figure 23 Strategies to improve access to eye care for Indigenous and other minority ethnic groups Identified from scoping reviews for Indigenous people and other non-dominant ethnic groups in high-income countries, mapped to the patient-centred access framework by Levesque et al.339 Randomised controlled trials are shown in bold. References can be found in appendix 1 (p 102).
Figure 23 Strategies to improve access to eye care for Indigenous and other minority ethnic groups Identified from scoping reviews for Indigenous people and other non-dominant ethnic groups in high-income countries, mapped to the patient-centred access framework by Levesque et al.339 Randomised controlled trials are shown in bold. References can be found in appendix 1 (p 102).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 326 references

Research works printed but not linked: 1

  1. Soleimani-Sefat, 2016, The needs and problems of students with visual impairment, J Soc Sci Hum Stud, 2, 8

Cited by

See all 1,624

Metadata

Authors
Burton, M. J., Ramke, J., Marques, A. P., Bourne, R. R. A., Congdon, N., Jones, I., Ah Tong, B. A. M., Arunga, S., Bachani, D., Bascaran, C., Bastawrous, A., Blanchet, K., Braithwaite, T., Buchan, J. C., Cairns, J., Cama, A., Chagunda, M., Chuluunkhuu, C., Cooper, A., Crofts-Lawrence, J., Dean, W. H., Denniston, A. K., Ehrlich, J. R., Emerson, P. M., Evans, J. R., Frick, K. D., Friedman, D. S., Furtado, J. M., Gichangi, M. M., Gichuhi, S., Gilbert, S. S., Gurung, R., Habtamu, E., Holland, P., Jonas, J. B., Keane, P. A., Keay, L., Khanna, R. C., Khaw, P. T., Kuper, H., Kyari, F., Lansingh, V. C., Mactaggart, I., Mafwiri, M. M., Mathenge, W., McCormick, I., Morjaria, P., Mowatt, L., Muirhead, D., Murthy, G. V. S., Mwangi, N., Patel, D. B., Peto, T., Qureshi, B. M., Salomão, S. R., Sarah, V., Shilio, B. R., Solomon, A. W., Swenor, B. K., Taylor, H. R., Wang, N., Webson, A., West, S. K., Wong, T. Y., Wormald, R., Yasmin, S., Yusufu, M., Silva, J. C., Resnikoff, S., Ravilla, T., Gilbert, C. E., Foster, A., & Faal, H. B.
Affiliations
  • Moorfields Eye Hospital NHS Foundation Trust (GB)
  • University of Auckland (NZ)
  • University of Cambridge (GB)
  • Queen's University Belfast (GB)
  • Sightsavers (GB)
  • Mbarara University of Science and Technology (UG)
  • Ministry of Health and Family Welfare (IN)
  • London School of Hygiene & Tropical Medicine (GB)
  • University of Geneva (CH)
  • St Thomas' Hospital (GB)
  • Leeds Teaching Hospitals NHS Trust (GB)
  • Ministry of Health (MZ)
  • National Museum of Mongolia (MN)
  • International Agency for the Prevention of Blindness (GB)
  • University of Cape Town (ZA)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • University of Michigan (US)
  • Emory University (US)
  • Johns Hopkins University (US)
  • Massachusetts Eye and Ear Infirmary (US)
  • Universidade de São Paulo (BR)
  • Ministry of Health (KE)
  • University of Nairobi (KE)
  • Seva Foundation (US)
  • Tilganga Institute of Ophthalmology (NP)
  • Heidelberg University (DE)
  • UNSW Sydney (AU)
  • L V Prasad Eye Institute (IN)
  • Instituto Mexicano de Oftalmología IAP (MX)
  • Muhimbili University of Health and Allied Sciences (TZ)
  • University of the West Indies (JM)
  • The University of Melbourne (AU)
  • Kenya Medical Training College (KE)
  • Christoffel Blinden Mission (DE)
  • Universidade Federal de São Paulo (BR)
  • Fred Hollows Foundation (AU)
  • Ministry of Health, Community Development, Gender, Elderly and Children (TZ)
  • World Health Organization (CH)
  • Beijing Tongren Hospital (CN)
  • United Nations (US)
  • National University of Singapore (SG)
  • World Health Organization Regional Office for the Americas (US)
  • Brien Holden Vision Institute (AU)
  • Aravind Eye Hospital (IN)
  • University of Calabar (NG)
Corresponding author
Burton, Matthew J
Venue
The Lancet Global Health
Publisher
Elsevier BV
Published
2021-04
Volume
9
Issue
4
Pages
e489-e551
ISSN
2214-109X (ISSN-L)
OpenAlex
W3130938027
Cited by
1,624
References
326
Citations by year
2026: 335 · 2025: 375 · 2024: 339 · 2023: 263 · 2022: 219 · 2021: 92
FWCI
34.95
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Global Health (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
  • Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
  • Anglia Ruskin Research Online (Anglia Ruskin University) (submittedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion, public-domain)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
Wellcome Trust
Topics
  • Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
Keywords
eye health, visual impairment, blindness, access to eye care, low- and middle-income countries, Sustainable Development Goals, productivity loss, population aging, rural population, ethnic minorities, quality of life, social inclusion, health equity, eye health policy, eye health workforce
MeSH terms
Global Burden of Disease, Sustainable Development, Blindness, Eye Diseases, Health Services Accessibility, Humans, Quality of Health Care, Quality of Life, Global Health, Cost of Illness, Advisory Committees

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. https://app.cochat.ai/papers/10.1016/s2214-109x(20)30488-5
The paper
Burton, M. J., Ramke, J., Marques, A. P., Bourne, R. R. A., Congdon, N., Jones, I., Ah Tong, B. A. M., Arunga, S., Bachani, D., Bascaran, C., Bastawrous, A., Blanchet, K., Braithwaite, T., Buchan, J. C., Cairns, J., Cama, A., Chagunda, M., Chuluunkhuu, C., Cooper, A., . . . Faal, H. B. (2021). The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(20)30488-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.